Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Proceedings of the National Academy of Sciences of the United States of America.
Times cited: 99
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.
Times cited: 684